An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Trial Profile

An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2018

At a glance

  • Drugs Rocapuldencel-T (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ADAPT
  • Sponsors Argos Therapeutics Inc
  • Most Recent Events

    • 05 Jun 2018 Interim results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 19 Apr 2018 According to an Argos Therapeutics media release, based on the recently submitted protocol amendment focused on four co-primary endpoints of survival and review of the interim data the Company does not believe that it would achieve these endpoints if the trial were to be continued. After consulting with the principal investigators, the company has decided to discontinue the trial and has informed the FDA of its decision.
    • 19 Apr 2018 Results of an interim analysis published in an Argos Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top